Your browser doesn't support javascript.
loading
Targeting nuclear ß-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Saenz, Dyana T; Fiskus, Warren; Manshouri, Taghi; Mill, Christopher P; Qian, Yimin; Raina, Kanak; Rajapakshe, Kimal; Coarfa, Cristian; Soldi, Raffaella; Bose, Prithviraj; Borthakur, Gautam; Kadia, Tapan M; Khoury, Joseph D; Masarova, Lucia; Nowak, Agnieszka J; Sun, Baohua; Saenz, David N; Kornblau, Steven M; Horrigan, Steve; Sharma, Sunil; Qiu, Peng; Crews, Craig M; Verstovsek, Srdan; Bhalla, Kapil N.
Afiliación
  • Saenz DT; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Fiskus W; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Manshouri T; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Mill CP; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Qian Y; Arvinas, Inc., 5 Science Park, New Haven, CT, 06511, USA.
  • Raina K; Arvinas, Inc., 5 Science Park, New Haven, CT, 06511, USA.
  • Rajapakshe K; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Soldi R; ß Cat Pharma, 2450 Holcombe Blvd. Suite J606, Houston, TX, 77021, USA.
  • Bose P; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Borthakur G; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Kadia TM; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Khoury JD; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Masarova L; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Nowak AJ; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Sun B; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Saenz DN; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Kornblau SM; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Horrigan S; ß Cat Pharma, 2450 Holcombe Blvd. Suite J606, Houston, TX, 77021, USA.
  • Sharma S; Translational Genomics Research Institute (TGen), 445 N. Fifth Street, Phoenix, AZ, 85004, USA.
  • Qiu P; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, GA, 30332, USA.
  • Crews CM; Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA.
  • Verstovsek S; Department of Chemistry, Yale University, New Haven, CT, 06520, USA.
  • Bhalla KN; Department of Pharmacology, Yale University, New Haven, CT, 06520, USA.
Leukemia ; 33(6): 1373-1386, 2019 06.
Article en En | MEDLINE | ID: mdl-30575820
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Núcleo Celular / Inhibidores de Proteínas Quinasas / Sinergismo Farmacológico / Beta Catenina / Trastornos Mieloproliferativos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Núcleo Celular / Inhibidores de Proteínas Quinasas / Sinergismo Farmacológico / Beta Catenina / Trastornos Mieloproliferativos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos